New drug Molnupiravir helps in faster recovery of mild covid patients
Molnupiravir the drug — an oral antiviral — when administered to mild Covid patients, helped them recover faster, in comparison to those who received standard of care (SOC, the treatment process followed by a doctor based on the patient’s requirements, illness and clinical circumstances) treatment alone.
The drug is a potent ribonucleoside analog (known to block RNA viruses associated with influenza-like diseases) that inhibits the replication of multiple RNA viruses (those that have ribonucleic acid as its genetic material), including SARS-CoV-2, the causative agent of Covid.
Cas. No.: 1955522-00-5